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Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein–Barr virus (EBV)-associated
and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection
could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC
is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established
ones. This causes difﬁculty in planning for cost-effective early detection strategies. Our study systematically evaluated six
established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp
remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect
Stage I, early stage and all NPC, respectively. Its speciﬁcity was 94.2% (113/120) against population controls and 90.4%
(113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-
29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset.
Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the speciﬁcity or
sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our
ﬁndings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening,
combining biomarkers to increase sensitivity or speciﬁcity and testing biomarkers from single sampled specimen to avoid
logistic problems of resampling.
What’s new?
Plasma Epstein–Barr virus (EBV) DNA is an established nasopharyngeal carcinoma (NPC) biomarker, but not all cases are
associated with EBV and its sensitivity for stage I NPC remains controversial. Meanwhile, most newly-reported NPC biomarkers
have neither been externally validated nor compared to established biomarkers. This study systematically evaluates six
established and four new biomarkers in NPC cases, population controls, and hospital controls. The ﬁndings provide evidence
to policymakers for improvement in NPC screening and monitoring strategies, covering considerations of opportunistic
screening, combining biomarkers to increase sensitivity/speciﬁcity, and testing multiple biomarkers on single specimens to
avoid the logistic problems of resampling.
Background
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy
originating from the fossa of Rosenmüller of the nasopharynx. Its
distribution is geographically distinct, with natives of Borneo
Island, people in Southeast Asia and the Southern part of China
having high age standardized rate (ASR) but is uncommon inmost
part of the world.1,2 Among the top 20 countries with highest inci-
dence andmortality rates of NPC,3 17 are low- andmiddle-income
countries (LMICs), 10 of which are located in Southeast Asia. It is
known that the family members of NPC patients have two to nine
folds higher risk in developing NPC.4–7 The lowest social class
group had 4.1 odds ratio in developing NPC.8 NPC is radiosensi-
tive when treated early, with 5-year overall survival rate ranging
from 78% to 100% (early stage) to as low as 26% (late stage and
recurrent cases).9–11 Recently, a study revealed that over 75% of
cancer patients in Southeast Asia experienced death or ﬁnancial
catastrophe within 1 year of cancer diagnosis, mainly due to the
lack of early detection and affordable cancer care.12 As themajority
of NPC patients present at late stage,13 early detection could be the
key to reduce the disease burden caused byNPC in LMICs.
Interaction among genes, environmental exposure and the
Epstein–Barr virus (EBV) are the key events leading toNPC patho-
genesis. Majority of NPC cases (>95%, except for the WHO
keratinizing NPC subtype) are associated with EBV.14 EBV is
commonly detected in the tumor cells, blood and urine of NPC
patients.15 Over decades of research, EBV serology and plasma
EBV DNA tests have become the established circulating bio-
markers known to have high diagnostic performance in dis-
tinguishing NPC from controls.15 Recent evidences showed that
combination of serum viral capsid antigen (VCA) IgA and EBV
nuclear antigen 1 (EBNA-1) IgA tests by ELISA could outperform
single serology marker test in a case–control study16 as well as in a
cluster randomized screening trial17 among the southern Chinese
populations. The percentage of early stage NPC cases (Stages I and
II) detected by the combination of these two serology markers dur-
ing screening were higher (68.3%) as compared to unscreened
populations in the screening towns (36.0%) and control towns
(25.7%).17 However, the seropositive rate of about 3% in a screen-
ing setting may still lead to a considerable burden on the resource
low health care system in LMICs to conduct close follow-up for
individuals with positive screening results. Meanwhile, plasma
EBV DNA test is long known to have high sensitivity and speciﬁc-
ity to distinguish NPC from controls when optimal experimental
protocols were carried out, but there were concerns about its utility
in detecting early stage NPC and recurrent NPC.15,18 Of note, these
EBVDNA case–control studies analyzed small sample size of Stage
I NPC cases.15,19 Recently, a large NPC screening study conducted
in Hong Kong demonstrated that plasma EBV DNA test (BamHI-
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W76 bp) could identify a signiﬁcantly higher proportion of partic-
ipants with early stage NPC as compared to the unscreened
historical cohort (70.6% vs. 19.2%).20 The same study group subse-
quently reported that EBV DNA fragment size proﬁles of NPC
patients are different from the small subset of general population
whowas transiently positive for plasma EBVDNA.21
According to the US National Cancer Institute’s Early Detection
Research Network, there are ﬁve phases for developing and validat-
ing biomarkers.22 Despite the established EBV DNA tests and EBV
serology tests which had already reach Phase 5 (Cancer Control),
the pursuit of newNPC biomarkers continues for twomain reasons:
(i) keratinizing NPC subtype and recurrent NPC have reduced or
absence of biomarkers originating from EBV,15 and (ii) EBV is also
associated with many other diseases23 and biomarkers of non-EBV
origin may help to reduce the false positive rate. Among the newly
reported circulating biomarkers for NPC, serum ebv-BART2-5p,
plasma ebv-miR-BART7-3p, ebv-miR-BART13-3p, hsa-miR-29a-
3p, hsa-miR-103a-3p, hsa-miR-483-5p and hsa-let-7c had moder-
ately good diagnostic accuracy (area under curve [AUC] > 0.7) in
detecting NPC against controls.24–26 Meanwhile, other newly
reported circulating biomarkers had AUC < 0.7,27–29 were iden-
tiﬁed from studies with normalization methods which are sub-
optimal for circulating biomarkers30,31 and/or required
additional processing or enrichment steps.19,32 The reliability
and diagnostic accuracy of these new biomarkers for early detec-
tion of NPC await validation by external independent studies
(Phase 2, Clinical Assay and Validation) and should be evalu-
ated together with the established EBV DNA and serology tests.
Malaysia is a country inhabited by multiethnic groups with dif-
ferent ASRs of NPC. Highest ASR of NPC (30 per 100,000) was
observed in Bidayuh males, followed by Bidayuh females, Chinese
males, Iban males and Kadazan males (10–20 per 100,000). Malay
males, Chinese females, Iban females and Kadazan females have
intermediate ASR of NPC (3.3–5.9 per 100,000), while lowest ASR
of NPC (0.6–1.3 per 100,000) was observed in Malay females,
Indian males and females.33–35 According to the Malaysian
National Cancer Registry Report 2007–2011, NPC was the cancer
with the highest ASR among Malaysian men between 26 and
45 years old.35 Despite the progress of NPC screening studies in
southern China, NPC screening is yet to be adopted in Malaysia,
due to less characterized population baseline values and uncer-
tainty in the application of single or combination of biomarkers for
screening. InMalaysia, histological examination of nasoendoscopic
biopsy samples remains the gold standard to diagnose NPC. Com-
puterized tomography is limited to major centers while magnetic
resonance imaging and positron emission tomography are not rou-
tinely available to most NPC patients. Due to the confusing and
nonspeciﬁc nature of early stage NPC symptoms,13 as well as the
invasive and difﬁcult accessibility of nasoendoscopic biopsy tests
mandatory to conﬁrm the presence of tumor (nasoendoscopy is
only performed by trained otorhinolaryngologists in major cen-
ters), late presentation is a common issue.13
Our study aimed to evaluate the diagnostic performance of
six established NPC biomarkers, consisting of two EBV DNA
(BamHI-W 76 bp and EBNA1 99 bp) and four anti-EBV anti-
bodies (early antigen [EA] IgA, EA IgG, EBNA-1 IgA and VCA
IgA), in local NPC cases, population controls and hospital con-
trols. In addition, the performance of four newly reported NPC
biomarkers, including one EBV DNA (BamHI-W 121 bp) and
three miRNAs (ebv-miR-BART7-3p, hsa-miR-29a-3p and hsa-
miR-103a-3p) were evaluated in a subset of our study. It is hoped
that single or combination of tests optimal for early detection and
prognosis of NPC can be identiﬁed to improve strategies for NPC
screening and monitoring.
Materials and Methods
Participants and blood samples collection
Participants were recruited from hospitals and National Blood
Bank from year 2008 to 2017. Ethics approval was obtained from
the Medical Research and Ethics Committee, Ministry of Health
Malaysia. Signed informed consent was obtained from histologi-
cally conﬁrmed NPC patients, population controls (apparently
healthy asymptomatic individuals) and hospital controls (patients
without any cancer, EBV related diseases or ear-nose-throat dis-
eases). Blood samples were collected in EDTA tubes and
processed within 4 hr. Blood tubes were centrifuged at room
temperature for 10 min at 2,500 RPM, and plasma aliquoted into
separate cryogenic tubes and stored at −80C. The numbers of
samples analyzed for each test are stated in Table 1. Staging for
NPC was based on the American Joint Committee on Cancer
(AJCC) 7th edition and completion of radical treatment was
deﬁned as receiving a minimum of 66 Gy of radiotherapy. Sur-
vival information was retrieved from National Registration
Department, Ministry of Home Affairs.
Measurement of plasma anti-EBV antibodies using ELISA
Plasma VCA IgA, EBNA-1 IgA, EA IgA and EA IgG were
measured according to manufacturer’s instructions (IBL Interna-
tional, Hamburg, Germany). The microtiter strips of VCA IgA
(RE57341), EBNA-1 IgA (RE57321), EA IgA (RE56211) and EA
IgG (RE57311) ELISA kits were precoated with VCA gp 125 afﬁnity
puriﬁed from P3HR1 cells, recombinant EBNA-1 p72 antigen
expressed in Sf9-cells, an immunodominant region of EA-D which
was afﬁnity puriﬁed from RAJI cells, and recombinant EA p54
expressed inEscherichia coli, respectively. First, plasma samples were
diluted in diluent buffer (1:401). Standard, control or diluted sam-
ples were aliquoted (100 μl each) into duplicate wells of microtiter
plates, followed by 60 min incubation at 25C or 37C and three
times washing (each time with 350 μl wash buffer per well). Then,
30 min or 1 hr incubation with 100 μl of enzyme conjugate was car-
ried out at 25C or 37C, followed by another washing step as
described previously. Twenty or 30 min incubation with 100 μl of
3,30,5,50-tetramethylbenzidine substrate solution was subsequently
carried out in the dark and the reaction was stopped by addition of
100 μl stop solution. Optical density was measured at 450 nm and
average results from duplicate wells were calculated. Levels of anti-
EBV antibodies in Unit/ml were interpolated from standard curve.
Tan et al. 3















Table 1. Diagnostic performance of 10 plasma biomarkers for detection of NPC
Comparison
BamHI-W 76 bp
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >0 copy/ml 29 1 113 7 94.7% 96.7% 94.2% 0.9726
Stages I and II NPC vs. PC >0 copy/ml 58 2 113 7 95.0% 96.7% 94.2% 0.9756
All NPC vs. PC >0 copy/ml 226 6 113 7 96.3% 97.4% 94.2% 0.9832
Stage I NPC vs. HC >0 copy/ml 29 1 113 12 91.6% 96.7% 90.4% 0.9615
Stages I and II NPC vs. HC >0 copy/ml 58 2 113 12 92.4% 96.7% 90.4% 0.9679
All NPC vs. HC >0 copy/ml 226 6 113 12 95.0% 97.4% 90.4% 0.9796
Comparison
EBNA1 99 bp
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >0 copy/ml 22 8 119 1 94.0% 73.3% 99.2% 0.8650
Stages I and II NPC vs. PC >0 copy/ml 48 12 119 1 92.8% 80.0% 99.2% 0.8988
All NPC vs. PC >0 copy/ml 200 32 119 1 90.6% 86.2% 99.2% 0.9303
Stage I NPC vs. HC >0 copy/ml 22 8 124 1 94.2% 73.3% 99.2% 0.8608
Stages I and II NPC vs. HC >0 copy/ml 48 12 124 1 93.0% 80.0% 99.2% 0.8941
All NPC vs. HC >0 copy/ml 200 32 124 1 90.8% 86.2% 99.2% 0.9281
Comparison
EA IgA
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC <1,006 U/ml1 4 4 83 29 72.5% 50.0% 74.1% 0.5368
Stages I and II NPC vs. PC >1,852 U/ml 17 13 81 31 69.0% 56.7% 72.3% 0.6226
All NPC vs. PC >1,510 U/ml 136 53 71 41 68.8% 72.0% 63.4% 0.6835
Stage I NPC vs. HC >823.0 U/ml 7 1 44 9 83.6% 87.5% 83.0% 0.8514
Stages I and II NPC vs. HC > 815.0 U/ml 27 3 44 9 85.5% 90.0% 83.0% 0.9094
All NPC vs. HC >1,002 U/ml 172 17 48 5 90.9% 91.0% 90.6% 0.9567
Comparison
EBNA-1 IgA
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >6,147 U/ml 4 4 107 6 91.7% 50.0% 94.7% 0.6565
Stages I and II NPC vs. PC >4,409 U/ml 10 19 100 13 77.5% 34.5% 88.5% 0.6196
All NPC vs. PC >5,217 U/ml 58 130 104 9 53.8% 30.9% 92.0% 0.6476
Stage I NPC vs. HC >5,080 U/ml 4 4 50 3 88.5% 50.0% 94.3% 0.7476
Stages I and II NPC vs. HC >2,988 U/ml 15 14 48 5 76.8% 51.7% 90.6% 0.7586
All NPC vs. HC >1,791 U/ml 117 71 43 10 66.4% 62.2% 81.1% 0.7886
Comparison
EA IgG
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >1,605 U/ml 8 0 60 52 56.7% 100.0% 53.6% 0.7031
Stages I and II NPC vs. PC >1,575 U/ml 28 2 60 52 62.0% 93.3% 53.6% 0.7991
All NPC vs. PC >5,322 U/ml 156 34 84 28 79.5% 82.1% 75.0% 0.8612
Stage I NPC vs. HC >1,642 U/ml 8 0 50 3 95.1% 100.0% 94.3% 0.9670
Stages I and II NPC vs. HC >1,481 U/ml 28 2 49 4 92.8% 93.3% 92.5% 0.9415
All NPC vs. HC >1,642 U/ml 185 5 50 3 96.7% 97.4% 94.3% 0.9765
Comparison
VCA IgA
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >731.5 U/ml 8 0 71 42 65.3% 100.0% 62.8% 0.7378
Staged I and II NPC vs. PC >731.5 U/ml 27 2 71 42 69.0% 93.1% 62.8% 0.7667
All NPC vs. PC >731.5 U/ml 180 8 71 42 83.4% 95.7% 62.8% 0.7979
Stage I NPC vs. HC >1,055 U/ml 6 2 51 2 93.4% 75.0% 96.2% 0.9033
Stages I and II NPC vs. HC >964.5 U/ml 25 4 50 3 91.5% 86.2% 94.3% 0.9115
All NPC vs. HC >1,022 U/ml 170 18 51 2 91.7% 90.4% 96.2% 0.9498
(Continues)
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Plasma DNA and RNA extractions
Frozen plasma samples were thawed and centrifuged at room
temperature for 10 min at 3,000 RPM to remove any cell debris
prior to DNA or RNA extractions. DNA extraction from 200 to
400 μl plasma per sample was performed using QIAamp DNA
Mini kit, while automated extraction of RNA from 400 μl
plasma per sample was carried out using miRNeasy Micro
Kit with QIAcube according to manufacturer’s protocols
(Qiagen, Hilden, Germany). In order to account for possible
plasma RNA extraction bias, 500 attomole of synthetic miRNA
cel-miR-39 (Integrated DNA Technologies, Coralville, IA) was
spiked into all plasma samples after mixing with QIAzol from
the miRNeasy Micro Kit (Qiagen). All DNA and RNA samples
were eluted in 50 and 25 μl of nuclease free water (Qiagen),
respectively.
Quantiﬁcation of plasma EBV DNA level
Three EBV DNA tests with different primers and hydrolysis
probes were conducted in our study (Supporting Information
Table S1). Quantitative polymerase chain reaction (qPCR) was
carried out using TaqMan Fast Advanced Master Mix in the
ABI7500 Fast Real-Time PCR system (Applied Biosystems, Foster
Table 1. Diagnostic performance of 10 plasma biomarkers for detection of NPC (Continued)
Comparison
BamHI-W 121 bp
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >0 copy/ml 14 6 48 1 89.9% 70.0% 98.0% 0.8459
Stages I and II NPC vs. PC >0 copy/ml 28 8 48 1 89.4% 77.8% 98.0% 0.8861
All NPC vs. PC >0 copy/ml 48 14 48 1 86.5% 77.4% 98.0% 0.8845
Stage I NPC vs. HC >0 copy/ml 14 6 8 4 68.8% 70.0% 66.7% 0.6333
Stages I and II NPC vs. HC >0 copy/ml 28 8 8 4 75.0% 77.8% 66.7% 0.6736
All NPC vs. HC >0 copy/ml 48 14 8 4 75.7% 77.4% 66.7% 0.7218
Comparison
ebv-miR-BART7-3p
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >5.565 FCOD 15 4 38 5 85.5% 78.9% 88.4% 0.8550
Stages I and II NPC vs. PC >4.145 FCOD 30 5 31 12 78.2% 85.7% 72.1% 0.8399
All NPC vs. PC >4.085 FCOD 52 19 31 12 72.8% 73.2% 72.1% 0.7737
Stage I NPC vs. HC ND ND ND ND ND ND ND ND ND
Stages I and II NPC vs. HC ND ND ND ND ND ND ND ND ND
All NPC vs. HC ND ND ND ND ND ND ND ND ND
Comparison
hsa-miR-29a-3p
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >9.760 FCOD1 6 12 23 0 70.7% 33.3% 100.0% 0.6763
Stages I and II NPC vs. PC >9.760 FCOD1 9 23 23 0 58.2% 28.1% 100.0% 0.5639
All NPC vs. PC <8.200 FCOD 25 21 15 8 58.0% 54.3% 65.2% 0.5071
Stage I NPC vs. HC ND ND ND ND ND ND ND ND ND
Stages I and II NPC vs. HC ND ND ND ND ND ND ND ND ND
All NPC vs. HC ND ND ND ND ND ND ND ND ND
Stages II to IVC NPC vs. PC <8.300 FCOD 22 6 14 9 70.6% 78.6% 60.9% 0.6250
Comparison
hsa-miR-103a-3p
Cutoff TP FN TN FP Accuracy Sensitivity Speciﬁcity AUC
Stage I NPC vs. PC >10.89 FCOD1 5 13 20 3 61.0% 27.8% 87.0% 0.5060
Stages I and II NPC vs. PC <9.270 FCOD 19 13 15 8 61.8% 59.4% 65.2% 0.5618
All NPC vs. PC <9.390 FCOD 31 15 15 8 66.7% 67.4% 65.2% 0.6144
Stage I NPC vs. HC ND ND ND ND ND ND ND ND ND
Stages I and II NPC vs. HC ND ND ND ND ND ND ND ND ND
All NPC vs. HC ND ND ND ND ND ND ND ND ND
Stages II to IVC NPC vs. PC <9.390 FCOD 22 6 15 8 72.5% 78.6% 65.2% 0.6918
All cutoff values were calculated based on Youden index from ROC analysis except BamHI-W 76 bp, EBNA-1 99 bp and BamHI-W 121 bp which had
cutoff set as >0 copy/ml.
1Cutoff is not practical due to biomarker not suitable for detection of early stage NPC.
Abbreviations: FCOD, fold change over detection limit; HC, hospital controls; PC, population controls; ND, not determined.
Tan et al. 5


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































City, CA) according to manufacturer’s instructions. A total of 5 μl
eluted DNA was used in 20 μl total reaction volume in each
qPCR well, and each sample was analyzed in triplicate wells. Each
qPCR plate contained no-template-control and serially diluted
Namalwa cell DNA samples as standard points for the construc-
tion of EBV DNA copy number standard curve. Namalwa cells
are known to have two integrated EBV genomes per cell.36 Accu-
rate dilution of Namalwa cell DNA standard points and quantiﬁ-
cation of EBV copy numbers by EBNA1 99 bp test were validated
by calibrating these Namalwa cell DNA standard points to the 1st
WHO International Standard for EBV for Nucleic Acid Ampliﬁ-
cation Techniques37 (NIBSC code: 09/260, Supporting Informa-
tion Table S2). Thermal cycling conditions include 50C for
2 min, 95C for 20 sec, and 40 cycles of 95C for 3 sec and 56C
for 30 sec. EBV DNA copy number was interpolated from the
Namalwa cell DNA standard curve and plasma EBV DNA level
was calculated using the following formula:




× Ve=V fð Þ× 1=a
where c = intercept, m = slope of the standard curve, Ve = DNA
elution volume, Vf = ﬁnal DNA volume used per qPCR well,
a = ml of plasma used for DNA extraction.
RT-qPCR validation of differential miRNA expression
Pooled reverse transcription (RT) of cel-miR-39, hsa-miR-
29a-3p and hsa-miR-103a-3p was carried out using commer-
cially available assays (Applied Biosystems) according to opti-
mized protocol which showed high reliability and
consistency.38,39 RT protocol, primers and probe sequences of
ebv-miR-BART7-3p were according to Zhang et al.24 RT
products of each sample, negative and positive controls were
analyzed in duplicate wells using TaqMan 2X Universal PCR
Master Mix, No AmpErase UNG in ABI7500 Fast Real-Time
PC HC I II III IVA/B IVC
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Figure 1. Evaluation of established plasma biomarkers to detect NPC against controls in our study. (a, b) Only low levels of plasma EBV DNA was
observed in small subset of population controls and hospital controls. The levels of plasma EBV DNA increased with the stages of NPC. (c–f) NPC patients
generally had higher plasma levels of anti-EBV antibodies as compared to controls but no obvious trend within NPC subgroups was observed. Samples
with undetectable plasma BamHI-W 76 bp and plasma EBNA1 99 bp were arbitrarily set as 0.001 copy/ml. HC, hospital control; PC, population control.
[Color ﬁgure can be viewed at wileyonlinelibrary.com]
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PCR system (Applied Biosystems) according to manufacturer’s
instructions. Data were normalized to cel-miR-39 (spike-in con-
trol) and fold change over detection limit was calculated.38,39
Statistical analysis
In GraphPad Prism software, Mann–Whitney test was used to
compare the mean rank differences between NPC and controls.
AUC values were generated from receiver operating characteristic
(ROC) curve analysis. In SPSS software, intraclass correlation coef-
ﬁcient (ICC) was obtained from average-measurement, absolute-
agreement, two-waymixed-effects model. Decision tree models for
NPC detection and prediction of overall survival were built with
sample size, decision tree growing methods, criteria and validation
parameters stated in Table 2.
Data availability
The data that support the ﬁndings of our study are available
from the corresponding author upon reasonable request.
Results
Plasma EBV DNA
Demographic and clinicopathological characteristics of NPC
patients and controls are shown in Supporting Information
Table S3. All 10 plasma biomarkers analyzed in our study did
not correlate with age and were not signiﬁcantly different
between different sex and ethnic groups (Supporting Informa-
tion Table S4). In our hands, results of EBV DNA test from
DNA extraction replicates had excellent test–retest reliability
(ICC > 0.95, Supporting Information Fig. S1a). We also found
that prior to plasma processing, plasma EBV DNA load was
fairly stable up to 6 hr in EDTA blood tube kept on bench at
room temperature (Supporting Information Fig. S1b).
Comparison of plasma EBV DNA load as measured by two
established EBV DNA tests (BamHI-W 76 bp and EBNA1
99 bp, Figs. 1a and 1b) were carried out between NPC patients
and controls. In general, plasma EBV DNA loads were signiﬁ-
cantly higher in NPC patients compared to controls, and only
low levels of plasma EBV DNA load was observed in a small
subset of controls (Figs. 1a and 1b). The level of plasma EBV
DNA increases with more advanced stages (Figs. 1a and 1b).
Similar to the large cohort NPC screening study in Hong
Kong,20 plasma EBV DNA load of >0 copy/ml was set as posi-
tive for both plasma EBV DNA tests (Table 1). This resulted in
94.2% and 99.2% speciﬁcity, respectively for BamHI-W 76 bp
and EBNA1 99 bp to identify NPC against population controls.
Speciﬁcity for BamHI-W 76 bp and EBNA1 99 bp to identify









































































PC I II III IVA/B IVC
Figure 2. Evaluation of newly reported plasma biomarkers to detect NPC against controls in our study subset. (a) Plasma EBV DNA trend as
measured by BamHI-W 121 bp is similar to the other two EBV DNA tests in Figure 1. (b) NPC patients generally had higher plasma levels of
ebv-miR-BART7-3p. A portion of healthy donors also had detectable level of plasma ebv-miR-BART7-3p. (c, d) Decreasing plasma levels of
hsa-miR-29a-3p and hsa-miR-103a-3p were observed from early stage NPC to advanced stage NPC. Plasma levels of these two human
miRNAs were not signiﬁcantly different between population controls and Stage I NPC (p > 0.05). Samples with undetectable plasma BamHI-W
121 bp were arbitrarily set as 0.001 copy/ml and samples with undetectable plasma ebv-miR-BART7-3p were arbitrarily set as −2 fold change
over detection limit. HC, hospital control; PC, population control. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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NPC against hospital controls were 90.4% and 99.2%, respec-
tively (Table 1). BamHI-W 76 bp being the EBV DNA test with
highest sensitivity to detect NPC had 96.7% (29/30) sensitivity to
detect Stage I NPC, 96.7% (58/60) sensitivity to detect early stage
(Stages I and II) NPC and 97.4% (226/232) sensitivity to detect
all NPC (Table 1). Based on recent ﬁndings that NPC patients
had signiﬁcantly longer fragment lengths of plasma EBV DNA
compared to non-NPCs,21 the new BamHI-W 121 bp test was
evaluated in a subset of our study samples with more early stage
NPC cases as well as cases with false positive results as deter-
mined by the two common EBV DNA tests (Fig. 2a). When test-
ing NPC against controls, improved speciﬁcity but decreased
sensitivity was found with BamHI-W 121 bp as compared to
BamHI-W 76 bp (Supporting Information Fig. S2).
Plasma anti-EBV antibodies
Moderately good to excellent test–retest reliability (ICC of
0.837–0.998) was achieved by commercially available ELISA
tests measuring plasma VCA IgA, EBNA-1 IgA, EA IgA and
EA IgG (Supporting Information Fig. S1c).
Comparison of ELISA results between NPC patients and con-
trols showed that plasma level of anti-EBV antibodies was gener-
ally higher in NPC patients as compared to controls. No obvious
trend was observed across different NPC stages and high levels
of plasma anti-EBV antibodies were observed in some controls
(Figs. 1c–1f ). Among these four anti-EBV antibody tests
evaluated in our study, VCA IgA and EA IgG consistently had
higher AUC values to detect early stage NPC against all controls,
while EBNA-1 IgA consistently showed the lowest AUC values
among the established biomarkers (Fig. 3 and Table 1).
Plasma miRNAs
Plasma ebv-miR-BART7-3p, hsa-miR-29a-3p and hsa-miR-
103a-3p were shortlisted for validation in a subset of our study
samples enriched with more early stage NPC cases (Table 1). In
general, plasma ebv-miR-BART7-3p levels were higher in NPC
compared to population controls and a portion of population
controls also had detectable plasma ebv-miR-BART7-3p (Fig. 2b
and Table 1). Similar median levels of plasma hsa-miR-29a-3p
and hsa-miR-103a-3p were observed between population con-
trols and Stage I NPC (Figs. 2c and 2d). It appeared that there
was a decreasing trend in plasma hsa-miR-29a-3p and hsa-miR-
103a-3p with the advancement of NPC stage (Figs. 2c and 2d).
Combination of plasma biomarkers for the detection of NPC
In order to evaluate if combination of plasma biomarkers may
improve NPC detection, decision tree modeling was carried out on
our data set comprising of 187 NPC cases and 106 population con-
trols with available results of six plasma biomarkers (Table 2 and
Supporting Information Table S3). BamHI-W 76 bp test alone
appeared to be sufﬁcient for the detection of NPC, and appeared to
be essential in all seven decision tree models (Table 2). Models 2, 5




































































































Figure 3. ROC analysis of 10 plasma biomarkers. BamHI-W 76 bp test (dark green dash line) consistently appeared to be the test with highest
AUC values while EBNA-1 IgA (purple line) consistently appeared to be the test with lowest AUC values among the six established
biomarkers. AUC values and numbers of test subjects can be viewed in Table 1. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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and 7 suggested that BamHI-W 76 bp test alone is sufﬁcient
(Table 2). Models 1, 3, and 4 suggested that combining VCA IgA
with BamHI-W 76 bp test can improve speciﬁcity at the expense of
reduced sensitivity while Model 6 suggested that combining EA
IgG with BamHI-W 76 bp test can further increase sensitivity at
the expense of decreased speciﬁcity (Table 2 and Supporting Infor-
mation Fig. S3).
Plasma EBV DNA load as a prognosis marker for NPC overall
survival
Survival information and test results of six plasma biomarkers
were available for a subset of our NPC cases who had completed
radical treatment (n = 80, Supporting Information Table S3).
ROC analysis and decision tree modeling were carried out to eval-
uate if any of these six plasma biomarkers had prognostic value
for the survival of these NPC patients (Table 2). According to
ROC analysis, EBNA1 99 bp was the only biomarker with
AUC > 0.7 (Table 2). With a cutoff at 14.06 copy/ml, EBNA1
99 bp could identify NPC patients with poor overall survival
(Fig. 4a) as well as poor progression-free survival (Fig. 4b) in both
early stage and late stage NPC (Fig. 4). Decision tree modeling
supported ﬁndings from this ROC analysis, revealing that EBNA1
99 bp with cutoff at about 14 copy/ml (Models 8–12) is sufﬁcient
for prognosis of survival while increasing EBNA1 99 bp cutoff to
138 copy/ml (Model 13) led to higher speciﬁcity but lower sensi-
tivity in prognosis of survival (Table 2). Notably, EBNA1 99 bp
with cutoff at about 14 copy/ml was still the only biomarker cho-
sen by decision tree modeling even though additional information
including age, sex, ethnicity, WHO type and AJCC staging were
added into the analysis (data not shown).
Discussion
In our study, 10 plasma biomarkers (BamHI-W 76 bp,
BamHI-W 121 bp, EBNA1 99 bp, EA IgA, EA IgG, EBNA-1
IgA, VCA IgA, ebv-miR-BART7-3p, hsa-miR-29a-3p and hsa-
miR-103a-3p) were systematically analyzed for early detection
and prognosis of NPC. These included established and newly
reported NPC biomarkers of EBV and human origin.
To our knowledge, published case–control studies which
reported 50–86% sensitivity of plasma EBV DNA test for Stage I
NPC had only analyzed two to 22 cases.15,19 Our study which
include larger sample size of Stage I NPC (n = 30) for plasma EBV
DNA test revealed 96.7% (29/30) sensitivity to detect Stage I NPC.
Besides larger sample size, our improved sensitivity ﬁndings may
be due to lower qPCR platform detection limit (25 copy/ml)
achieved with usage of more advanced qPCR master mix in our
study as compared to other studies.15,19 Our ﬁndings from com-
parison of BamHI-W 121 bp test and BamHI-W 76 bp test
(Supporting Information Fig. S2) support the notion that the larger
the qPCR amplicon size, the more speciﬁc but less sensitive is the
EBV DNA qPCR test. This is consistent with the ﬁndings reported
earlier which compared the performance of EBNA1 213 bp test
and EBNA1 99 bp test.40 It is estimated that increase in input
volume by eight times may compensate the sensitivity issue of
BamHI-W121 bp test as compared to BamHI-W76 bp test, hypo-
thetically from qPCR Cq 40 (undetected) to Cq 37, but will incur
higher cost and larger effort in sample processing andDNA extrac-
tion. Interestingly, four hospital controls were positive in both
plasma BamHI-W 76 bp and BamHI-W 121 bp tests (Supporting
Information Fig. S2). It is possible that these tests were sensitive
enough to detect NPC in cases which were too early to be detected
clinically. A follow-up on these individuals to check on event of
NPCwill be interesting.
In the EBV genome, there is only one copy of EBNA1 gene
while BamHI-W region may be reiterated by 7 to 11 repeats.41
Prevalent EBV in different populations may differ in the numbers

















































Early stage, >14.06 copy/ml
Late stage, >14.06 copy/ml
Early stage, <14.06 copy/ml
Late stage, <14.06 copy/ml
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(b)
Figure 4. Prognostic value of EBNA1 99 bp test. NPC patients with
plasma EBNA1 99 bp >14.06 copy/ml had poorer (a) overall survival
and (b) progression-free survival as compared to those with less
plasma EBNA1 99 bp level. EBNA1 99 bp is a good prognostic
marker regardless of early or late stages. [Color ﬁgure can be viewed
at wileyonlinelibrary.com]
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pretreatment plasma BamHI-W 76 bp level deduced from one
cohort not optimal for another cohort.42–44 If plasma BamHI-W
76 bp test results are intended to be used for prognosis, EBV DNA
clearance rate calculated from pretreatment and posttreatment
plasma EBVDNA loadmay be analyzed to rule out interindividual
variability. Indeed, in a systematic review and meta-analysis on the
prognosis of NPC by plasma BamHI-W 76 bp test, Zhang et al.
showed that cutoff for EBV DNA clearance rate was comparable
among studies cohort.42 In our study, pretreatment plasma EBNA1
99 bp and BamHI-W 76 bp tests had similar prognostic values
(AUC 0.709 and 0.680, respectively). Unlike BamHI-W 76 bp test,
pretreatment plasma EBNA1 99 bp test is not affected by inter-
individual variability and do not require multiple sampling to
calculate EBVDNA clearance rate. It would be interesting to inves-
tigate if the cutoff value of pretreatment plasma EBNA1 99 bp level
deduced in our study is applicable to future follow-up studies.
Our study had served as an external independent study and
validated the diagnostic performance of two newly reported bio-
markers (BamHI-W 121 bp and ebv-miR-BART7-3p). Speciﬁcity
of ebv-miR-BART7-3p appeared to be less optimal as it was
detected in about 28% (12/43) of population controls (Table 1),
which is in line with recent ﬁndings from Ramayanti et al.32 but
not Gao et al.29 The discrepancy may be due to the differences in
PCR primers. Meanwhile the diagnostic performance of hsa-miR-
29a-3p and hsa-miR103a-3p reported elsewhere25 could not be
reproduced in our study, possibly due to inclusion of more early
stage NPC and less advanced stage NPC in our analysis. Consis-
tent with ﬁndings from a previous report,25 differences in plasma
hsa-miR-29a-3p levels seemed to be more apparent only when
comparing controls to advanced stage NPC (Fig. 2c). It is possible
that four other miRNAs (ebv-BART2-5p, ebv-miR-BART13-3p,
hsa-miR-483-5p and hsa-let-7c) that are not included for valida-
tion in our study may perform well as early diagnosis markers for
NPC. EBV DNA markers are already well established for NPC
screening. From a clinical utility viewpoint, the additional value of
including non-EBV markers may be higher than the additional
value of including another EBV marker in the NPC detection
panel. Our study indicates that much effort is still needed to iden-
tify a combination panel of EBV markers and non-EBV markers
that will beneﬁt the detection of not only the majority of NPC
cases which are EBV positive but also the small subset of NPC
cases which are EBV negative.
Conclusions
Our study provides important information to policy makers in
LMICs who have limited health care resources to plan a more
cost-effective NPC screening and monitoring strategy for the
apparently healthy asymptomatic controls. We showed that the
diagnostic performance of established biomarkers to detect NPC
in local general population were comparable to ﬁndings of studies
from another NPC endemic area15 and plasma BamHI-W 76 bp
test is superior for early detection of NPC. Comparison of plasma
biomarkers in NPC patients and local hospital controls suggests
that plasma EBV DNA test could identify NPC cases among indi-
viduals who visit the hospital for other conditions in local setting,
thus allowing for opportunistic screening. Combined biomarker
tests from single sampled specimens can improve NPC detection
speciﬁcity (with slight decrease in sensitivity) and avoid logistic
problems of resampling. Plasma EBNA1 99 bp test may have
important prognostic value and could be used to stratify NPC
patients for different clinical management.
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